A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
Objective
Primary: To determine the feasibility of identifying a targeted agent by molecular methods and incorporating that agent into standard upfront high risk neuroblastoma treatment in cycles 3-6 of induction. Following standard consolidation therapy with ASCT, XRT (if indicated) and standard maintenance therapy with Ch14:18 antibody and cis-retinoic acid, the feasibility of adding further maintenance therapy with DFMO will also be assessed. Secondary: Monitor for acute toxicity To measure the response of treatments chosen (Voluntary) To explore the relationship between tumor phenotype/genotype and response by permitting use of tumor tissue in a correlative biologic study